Adage Capital Partners Gp, L.L.C. Eye Point Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $52.3 Billion
- Q2 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,591,420 shares of EYPT stock, worth $29 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
3,591,420
Previous 4,756,299
24.49%
Holding current value
$29 Million
Previous $98.3 Million
68.22%
% of portfolio
0.06%
Previous 0.19%
Shares
9 transactions
Others Institutions Holding EYPT
# of Institutions
163Shares Held
58.2MCall Options Held
224KPut Options Held
1.41M-
Cormorant Asset Management, LP Boston, MA8.33MShares$67.2 Million5.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$41.8 Million1.88% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$30.4 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.65MShares$29.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.77MShares$22.4 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $275M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...